<DOC>
	<DOCNO>NCT02581137</DOCNO>
	<brief_summary>This phase IIa trial study well metformin hydrochloride work prevent oral cancer patient oral premalignant lesion ( oral leukoplakia erythroplakia ) . Oral premalignant lesion look like red whitish plaque lesion mouth rub associate high risk cancer . Metformin hydrochloride may help prevent oral cancer form patient oral premalignant lesion .</brief_summary>
	<brief_title>Metformin Hydrochloride Preventing Oral Cancer Patients With Oral Premalignant Lesion</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine clinical response oral premalignant lesion 12-14 week metformin ( metformin hydrochloride ) intervention . SECONDARY OBJECTIVES : I. Histologic response metformin intervention target lesion . II . Tissue-based biomarkers : metformin effect cell proliferation molecular target target lesion normal tissue ( marker cell proliferation , Ki67 , molecular target metformin , include , order priority , phosphorylated ribosomal protein S6 kinase [ pS6 ] , phosphorylated v-akt murine thymoma viral oncogene homolog 1 [ pAKT ] S473 , phosphorylated eukaryotic translation initiation factor 4E-binding protein 1 [ p4EBP ] , phosphorylated acetyl-CoA carboxylase alpha [ pACC ] ) . III . Tissue-based biomarkers : expression dysregulated molecular mechanism organic cation transporter 3 ( OCT 3 ) target lesion normal tissue , include , order priority , epidermal growth factor receptor ( EGFR ) , phosphorylated ( p ) EGFR , tumor protein 53 ( p53 ) , phosphatase tensin homolog ( PTEN ) , phosphorylated mitogen-activated protein kinase 1 ( pERK ) , cyclin-dependent kinase inhibitor 2A ( p16 ) , OCT3 . IV . Tissue-based biomarkers : target analysis cancer-associated gene target lesion blood deoxyribonucleic acid ( DNA ) . V. Serum saliva base biomarkers : metformin effect serum metabolic marker ( C-peptide , glycosylated hemoglobin [ HbA1c ] ) . VI . Serum saliva base biomarkers : metformin concentration serum saliva . VII Serum saliva base biomarkers : metformin effect serum saliva inflammatory angiogenic cytokine , include interleukin ( IL ) -6 , IL-8 , growth-related oncogene-1 ( GRO-1 ) , vascular endothelial growth factor ( VEGF ) . OUTLINE : Patients receive extended-release metformin hydrochloride orally ( PO ) daily ( QD ) 2 week twice daily ( BID ) 10-12 week . Treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow 2-4 week .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Leukoplakia , Oral</mesh_term>
	<mesh_term>Leukoplakia</mesh_term>
	<mesh_term>Erythroplasia</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Participants oral leukoplakia erythroplakia mild , moderate , severe histologic dysplasia , hyperplasia associate mechanical factor illfitted denture Measurable disease minimum lesion size 8 x 3 mm initial biopsy Karnofsky performance status &gt; = 70 % Leukocytes &gt; = 3,000/microliter Absolute neutrophil count &gt; = 1,000/microliter Platelets &gt; = 100,000/microliter Total bilirubin = &lt; 1.5 × institutional upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) ( serum glutamic oxaloacetic transaminase [ SGOT ] ) /alanine aminotransferase ( ALT ) ( serum glutamate pyruvate transaminase [ SGPT ] ) = &lt; 1.5 × institutional ULN eGFR &gt; 40 mL/min use CockcroftGault equation Life expectancy &gt; 3 month Willing use adequate contraception ( barrier method , abstinence , subject vasectomy partner use effective birth control postmenopausal ) duration study participation Ability take oral medication Ability understand willingness sign write informed consent document Patients diabetes take insulin oral agent History diabetic ketoacidosis Participants may receive investigational agent within past 3 month History allergic reaction attribute compound similar chemical composition metformin prior use metformin within last year Uncontrolled intercurrent illness include , limited , ongoing active infection , human immunodeficiency virus ( HIV ) positive , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement Oral carcinoma situ History chronic alcohol use abuse define one following : ) average consumption 3 alcohol contain beverage daily past 12 month ; b ) consumption 7 alcoholic beverage within 24 hour ( hr ) period past 12 month HbA1c &gt; 8 % Pregnancy nursing woman Acute chronic liver disease , evidence hepatitis ( infectious autoimmune ) , cirrhosis portal hypertension History renal disease History prior head neck squamous cell carcinoma ( HNSCC ) unless curatively treat &gt; = 1 year Have receive chemotherapy and/or radiation malignancy ( exclude nonmelanoma skin cancer cancer confine organ removal treatment ) past 2 year ; ongoing adjuvant hormonal therapy breast cancer allow</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>